Today's Rundown UPDATE: Eli Lilly kick-starts speedy FDA review for Alzheimer's hopeful donanemab—and a one-on-one test against Aduhelm Johnson & Johnson goes local to help Black, Hispanic patients left behind by health inequality BD primes Amazon rollout of smartphone-based rapid COVID-19 test Democrats opposed to drug price reform are among those who received the most in donations from the pharma industry: report Moody's: Hospitals, staffing agencies shouldering the labor shortage while insurers are largely immune Novartis dumps Rett gene therapy caught up in Zolgensma scandal in cull of pipeline prospects Lilly, Pfizer stop development of osteoarthritis drug after FDA rejection, extending bleak run for NGF inhibitors As Lilly gears up for key 2022 launches, Trulicity, Taltz and more drive solid growth UHS' acute care volumes, revenues rose as COVID-driven labor shortages shuttered its behavioral services MIT researchers leverage nanotube sensor to detect COVID in five minutes Trice Medical nabs first FDA go-ahead for disposable arthroscope with 25-degree view Inclusion of women in stroke trials hasn't changed in 30 years: study What providers say are the biggest challenges of tracking social risk factors in patients Featured Story | By Ben Adams The great Alzheimer's R&D resurgence continues as Eli Lilly nabs an accelerated FDA review for its mixed bag drug donanemab, while also plotting direct head-to-head tests against Biogen’s new and controversial therapy Aduhelm. read more |
| |
|---|
|
Top Stories By Sharon Klahr Coey When it comes to health equity, Johnson & Johnson believes in going local for advice. The pharma’s latest innovation challenge bears that out by focusing on six cities—and by seeking suggestions directly from the people healthcare is leaving behind. read more By Andrea Park The biggest shopping days of the year are right around the corner, and this Cyber Monday, BD is making it easier than ever to stock up on COVID-19 tests. The diagnostic developer’s smartphone-based rapid antigen test began its commercial rollout this week, with the test available for purchase through Amazon. read more By Kevin Dunleavy Democrats accounted for roughly 60% of the $177 million in industry lobbying and campaign donations. And the contributions appear to be working, as those in the party who are most opposed to reducing drug prices are among the ones who benefited most from the influence-peddling, shows Reuters in an analysis of public data. read more By Dave Muoio Hospitals will continue to see a labor-related hit to their bottom lines well into 2022 and have limited avenues to pass along those costs, according to a new report. Health insurers, on the other hand, are positioned to promptly adjust their business to offset an increase in medical expenses. read more By Nick Paul Taylor Novartis has scrapped work on its Rett syndrome gene therapy AVXS-201 after finding the data don’t support further development. The action follows Novartis’ decision to gather extra data on the candidate in response to data manipulation during development of Zolgensma. read more By Nick Paul Taylor The NGF inhibitor class has claimed yet another victim. After seeing regulators on both sides of the Atlantic knock back filings for approval, Eli Lilly and Pfizer have stopped global clinical development of tanezumab. read more By Eric Sagonowsky While Eli Lilly's Alzheimer's disease hopeful donanemab stole most of the headlines for the drugmaker on Tuesday, the company's stable of approved drugs continued on their growth path. The company posted a double-digit sales increase in the third quarter and is getting ready for some highly anticipated launches. read more By Dave Muoio The for-profit chain missed analysts' earnings estimates but saw revenue and acute care volume growth during the third quarter of 2021. read more By Andrea Park Most of the highly accurate, lab-quality molecular tests for COVID-19 depend on scarce and often pricey reagents, while those that don't end up sacrificing diagnostic accuracy. A group of MIT scientists has developed new sensor technology that may achieve the best of both worlds. read more By Andrea Park Though disposable needle arthroscopes have become increasingly popular due to their lower risk of contamination and less invasive profile, full-size reusable arthroscopes are still the gold standard for surgeons hoping to get a comprehensive look inside a patient’s joints. Until now, that is. read more By Kyle LaHucik The average prevalence of stroke in women is about 48%, whereas about 37.4% of the nearly 589,000 patients in clinical trials between 1990 and 2020 were women, according to a new study. read more By Anastassia Gliadkovskaya Social and structural drivers determine 70% of health outcomes. But physicians face many challenges trying to track them. read more |
